Government-Owned Inventions; Availability for Licensing, 12976-12977 [2017-04501]

Download as PDF mstockstill on DSK3G9T082PROD with NOTICES 12976 Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Integrative Nutrition and Molecular Endocrinology. Date: March 29, 2017. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451–6319, rojasr@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Basic Research in Cancer Health Disparities/ Diversity. Date: March 30–31, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Ola Mae Zack Howard, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4192, MSC 7806, Bethesda, MD 20892, 301–451– 4467, howardz@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Mycobacterial induced immunity in HIVinfected and uninfected individuals. Date: March 30, 2017. Time: 8:30 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910. Contact Person: Jingsheng Tuo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, Bethesda, MD 20892, 301–451–8754, tuoj@ nei.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA– RM16–007: Transformative Research Award Review. Date: March 31, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Ave., Bethesda, MD 20814. Contact Person: Raymond Jacobson, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5858, MSC 7849, Bethesda, MD 20892, 301–996– 7702, jacobsonrh@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA– RM16–007: Transformative Research Award Review. Date: March 31, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 Contact Person: Raymond Jacobson, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5858, MSC 7849, Bethesda, MD 20892, 301–996– 7702, jacobsonrh@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA HD– 17–008: Autism Centers of Excellence: Networks (R01). Date: March 31, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015. Contact Person: Jane A. DoussardRoosevelt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435–4445, doussarj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: Review of Program Project. Date: March 31, 2017. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jose H. Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301–435– 1137, guerriej@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 2, 2017. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–04484 Filed 3–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental and Craniofacial Research; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; NIDCR Loan Repayment Program SEP. Date: March 29–31, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Latarsha J. Carithers, Ph.D., Scientific Review Officer, Division of Extramural Activities, NIDCR, 6701 Democracy Boulevard, Suite 672, Bethesda, MD 20892, 301–594–4859, latarsha.carithers@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: March 2, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–04482 Filed 3–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUMMARY: E:\FR\FM\08MRN1.SGM 08MRN1 Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices SUPPLEMENTARY INFORMATION: Technology description follows. AMA1–RON2 Complex-Based Vaccine Against Malaria Description of Technology This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in in vitro assays, but protection has so far not translated to in vivo human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells (RBCs). Vaccination with uncomplexed AMA1 and RON2 did not protect against lethal malaria. However, vaccination with a pre-formed AMA1– RON2 complex, highlighted in this technology, produced antibodies that protected against lethal malaria in an in vivo mouse model (P. yoelli) and blocked the entry of human malaria parasites into RBCs in vitro. Additionally, the inhibitory antibody response induced by the AMA1–RON2 complex was greater than AMA1 alone or when AMA1 and RON2 proteins were administered in a un-complexed form. Immunization using the AMA1–RON2 complex of this technology represents a candidate for an effective malaria vaccine against multiple Plasmodium species. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • Malaria vaccine Competitive Advantages Lower-cost malarial prevention for developing/developed countries. mstockstill on DSK3G9T082PROD with NOTICES Development Stage • Early-stage. • In vitro data available. • In vivo data available (animal). Inventors: Prakash Srinivasan and Louis Miller (NIAID). 1. Publications: Srinivasan P, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 Acad Sci U S A. 2011 Aug 9;108(32):13275–80. [PMID 21788485]. 2. Srinivasan P, et al. Disrupting malaria parasite AMA1–RON2 interaction with a small molecule prevents erythrocyte invasion. Nat Commun. 2013;4:2261. [PMID 23907321]. Intellectual Property: HHS Reference No. E–066–2013/0—U.S. Provisional Application No. 61/841,479 filed 01 Jul 2013; PCT Application No. PCT/ US2014/045065, filed July 1, 2014; European Application No. 14742116.8, filed July 1, 2014 (pending); U.S. Application No. 14/902,117, filed August December 30, 2015 (pending); and Chinese Application No. 201480037643.1, filed December 31, 2015 (pending). Licensing Contact: Peter Tung, 240– 669–5483; peter.tung@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability and interest from parties interested in collaborative research to further develop, evaluate or commercialize AMA1–RON2 vaccine by providing well established human adjuvants and clinical trial funding. For collaboration opportunities, please contact Peter Tung, 240–669–5483; peter.tung@nih.gov. Dated: February 24, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–04501 Filed 3–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 12977 Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–16– 115: Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir. Date: March 28, 2017. Time: 10:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Barna Dey, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, Bethesda, MD 20892, 301–451–2796, bdey@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Basic Research on HIV Persistence. Date: March 28, 2017. Time: 1:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Contact Person: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Barna Dey, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, Bethesda, MD 20892, 301–451–2796, bdey@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Research. Date: March 29, 2017. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: C–L Albert Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4146, MSC 7806, Bethesda, MD 20892, 301–435– 1016, wangca@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Vaccine, Host Defense and Inflammation. Date: March 29, 2017. Time: 3:00 p.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call). Contact Person: Betty Hayden, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4206, MSC 7812, Bethesda, MD 20892, 301–435– 1223, haydenb@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) E:\FR\FM\08MRN1.SGM 08MRN1

Agencies

[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Pages 12976-12977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04501]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

[[Page 12977]]


SUPPLEMENTARY INFORMATION: Technology description follows.

AMA1-RON2 Complex-Based Vaccine Against Malaria

Description of Technology

    This technology relates to a malaria vaccine composed of a protein 
complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 
(RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium 
invasion machinery and is a leading candidate for antimalarial vaccine 
development. AMA1-based vaccines have shown ability to block red cell 
invasion in in vitro assays, but protection has so far not translated 
to in vivo human infections. NIAID investigators have demonstrated that 
interaction between AMA1 and RON2 (or peptide thereof) is essential for 
malaria parasites to successfully enter human red blood cells (RBCs). 
Vaccination with un-complexed AMA1 and RON2 did not protect against 
lethal malaria. However, vaccination with a pre-formed AMA1-RON2 
complex, highlighted in this technology, produced antibodies that 
protected against lethal malaria in an in vivo mouse model (P. yoelli) 
and blocked the entry of human malaria parasites into RBCs in vitro. 
Additionally, the inhibitory antibody response induced by the AMA1-RON2 
complex was greater than AMA1 alone or when AMA1 and RON2 proteins were 
administered in a un-complexed form.
    Immunization using the AMA1-RON2 complex of this technology 
represents a candidate for an effective malaria vaccine against 
multiple Plasmodium species.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

 Malaria vaccine

Competitive Advantages

    Lower-cost malarial prevention for developing/developed countries.

Development Stage

     Early-stage.
     In vitro data available.
     In vivo data available (animal).
    Inventors: Prakash Srinivasan and Louis Miller (NIAID).
    1. Publications: Srinivasan P, et al. Binding of Plasmodium 
merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc 
Natl Acad Sci U S A. 2011 Aug 9;108(32):13275-80. [PMID 21788485].
    2. Srinivasan P, et al. Disrupting malaria parasite AMA1-RON2 
interaction with a small molecule prevents erythrocyte invasion. Nat 
Commun. 2013;4:2261. [PMID 23907321].
    Intellectual Property: HHS Reference No. E-066-2013/0--U.S. 
Provisional Application No. 61/841,479 filed 01 Jul 2013; PCT 
Application No. PCT/US2014/045065, filed July 1, 2014; European 
Application No. 14742116.8, filed July 1, 2014 (pending); U.S. 
Application No. 14/902,117, filed August December 30, 2015 (pending); 
and Chinese Application No. 201480037643.1, filed December 31, 2015 
(pending).
    Licensing Contact: Peter Tung, 240-669-5483; peter.tung@nih.gov. 
Collaborative Research Opportunity: The National Institute of Allergy 
and Infectious Diseases is seeking statements of capability and 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize AMA1-RON2 vaccine by providing well 
established human adjuvants and clinical trial funding. For 
collaboration opportunities, please contact Peter Tung, 240-669-5483; 
peter.tung@nih.gov.

    Dated: February 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04501 Filed 3-7-17; 8:45 am]
BILLING CODE 4140-01-P